Chelsie Derman is an associate editor for 

who covers allergy and  psychiatry. She joined MJH Life Sciences in September 2023 after graduating from The College of New Jersey with a bachelor’s degree in journalism and professional writing. In her free time, she enjoys creative writing and reading.

March 2026 featured a range of developments across psychiatry, including emerging psychedelic therapies, accelerated neuromodulation strategies, ethical considerations around artificial intelligence in mental health care, and new observational data linking metabolic therapies to psychiatric outcomes.

This month in review features the top 6 headlines in psychiatry.

Your Patient's New Therapist Is an AI. Now What?

Growing patient use of generative artificial intelligence tools for mental health support prompted discussion among psychiatrists and ethicists regarding safety, oversight, and clinical integration. Experts emphasized that patients are increasingly turning to conversational AI platforms for therapy-like interactions, raising concerns about accuracy, crisis management, and therapeutic boundaries. Clinicians highlighted the need for guidance on how to counsel patients using these tools, while acknowledging potential benefits such as increased accessibility and stigma reduction.

The discussion underscored that AI-based support may complement, but not replace, clinician-delivered psychotherapy, particularly for patients with complex psychiatric conditions or suicide risk.

 Richard Miller, MD (Elwyn Adult Behavioral Health), Hans Eriksson, MD, PhD (HMNC Brain Health), and Darlene King, MD (University of Texas Southwest Medical Center).

Latest Psychedelic Research in Depression

Single-Day GH001 for TRD Shows Rapid Response, With Michael E. Thase, PhD

A phase 2b trial of inhaled mebufotenin (GH001) demonstrated rapid and clinically meaningful improvement in treatment-resistant depression (TRD) following a single-day individualized dosing regimen. Participants received up to 3 escalating doses within 1 treatment session, with symptom improvements observed within 1 week.

In a randomized cohort, remission by day 8 occurred in 57.5% of treated patients compared with none receiving placebo, with a large effect size and rapid onset of benefit. Investigators highlighted the potential scalability of a single-day psychedelic-based intervention relative to multi-session treatment models.

Psychedelic Therapy Matches Efficacy of Antidepressants in MDD, With Balázs Szigeti, PhD

A meta-analysis evaluating psychedelic-assisted therapy versus antidepressants in major depressive disorder (MDD) found comparable symptom improvement when accounting for trial blinding differences. Investigators noted that psychedelic-assisted therapy produced robust antidepressant effects but did not demonstrate superiority over open-label antidepressant treatment.

The findings suggested psychedelic therapy may expand treatment options rather than replace established pharmacotherapy, with further research needed to assess functional outcomes and real-world implementation.

Accelerated Deep TMS Matches Standard Outcomes in TRD in 6 Days

Accelerated deep transcranial magnetic stimulation (dTMS) delivered over 6 days produced clinical outcomes comparable to standard multiweek treatment in MDD. A multisite noninferiority trial showed similar response and remission rates while shortening treatment duration.

Accelerated protocols also demonstrated faster symptom improvement and reduced time to remission, supporting their potential to improve access and adherence among patients with treatment-resistant depression.

Accelerated rTMS Matches Conventional Protocol in TRD, With Andrew Leuchter, MD

Separate data comparing accelerated repetitive TMS (rTMS) to conventional once-daily treatment found both approaches produced significant reductions in depressive symptoms, with no statistically significant difference in efficacy.

Investigators noted that compressing treatment into a single week may improve adherence and reduce disruption to daily functioning, offering practical advantages for patients and clinics.

Semaglutide Linked to Lower Suicidality Risk in Diabetes, With Mark Taylor, MD

Real-world registry data suggested glucagon-like peptide-1 receptor agonists, including semaglutide, were associated with reduced suicidality, anxiety, and psychiatric-related sick leave among patients with type 2 diabetes. Investigators used a within-individual design comparing treatment and non-treatment periods for the same patients, strengthening causal inference.

The findings counter earlier safety concerns and highlight potential mental health benefits of metabolic therapies, although experts emphasized these agents should not be considered primary psychiatric treatments.

Articles

March 2026 psychiatry developments spanned generative AI adoption, psychedelics for depression, accelerated neuromodulation, and metabolic-psychiatric observational signals. Clinicians and ethicists flagged safety, boundary, and crisis-management gaps as patients increasingly use conversational AI for therapy-like support, positioning AI as adjunctive rather than substitutive care. In depression, inhaled mebufotenin (GH001) produced rapid TRD improvement after a single-day session, while meta-analytic data suggested psychedelic-assisted therapy performs similarly to antidepressants when blinding is considered. Accelerated TMS regimens achieved noninferior outcomes within days. Registry analyses linked GLP-1RAs to lower suicidality indicators.

Rapid psychedelic therapies, accelerated TMS protocols, AI-driven care debates, and semaglutide’s link to reduced suicidality shaped psychiatry headlines in March 2026.

News

news page, resources on the topics of disease- and specialty-specific medical news and expert insight can be found. Content includes articles, interviews, videos, podcasts, and breaking news on health care research, treatment, and drug development.

Clinical

clinical page is a resource for content on every specialty, disease, and topic available on our medical news site.

Psychiatry

Psychiatry condition center page is a comprehensive resource for clinical news and insights on mental illnesses. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for depression, schizophrenia, bipolar disorder, anxiety, and more.

Major Depressive Disorder

Major Depressive Disorder condition center page, resources on the topics of medical news and expert insight into depression can be found. Content includes articles, interviews, videos, podcasts, and breaking news on MDD research, treatment, and drug development.

6 Psychiatry Headlines You Missed in March 2026 

Ryan Livingston joined the MJH Life Sciences team in March of 2025, shortly after graduating from TCNJ with a bachelor’s degree in English. He enjoys creative writing, reading, and scuba diving. He can be reached at rlivingston@mjhlifesciences.com.

American College of Cardiology (ACC) Scientific Sessions 2026

 saw the presentation of a slew of major, practice-changing studies and trials. Between fractional flow reserve (FFR) angiography in patients with coronary artery disease (CAD) from the ALL-RISE trial to mavacamten’s positive efficacy data in adolescent patients with 

obstructive hypertrophic cardiomyopathy (oHCM)

, major data was presented for just about every major disease state in cardiology.

In light of the sheer volume of new research, the editorial team at 

 has collected 6 of the most practice-changing results from ACC.26. Catch up on any major study data you may have missed during the conference below:


FFR Angiography Noninferior to Pressure-Wire Strategy in CAD Analysis, With William Fearon, MD


Presented by William Fearon, MD, professor of medicine and director of interventional cardiology at Stanford, the ALL-RISE study proved the noninferiority of angiography-guided FFR compared to a pressure-wire-guided strategy in patients with CAD. Enrolling a total of 1930 patients, the trial demonstrated a 98.5% success rate for FFR angiography compared to a 98.6% success rate for pressure-wire-based measurements. The mean time to calculate the assessment was 6 minutes in the FFRangio group and 8 in the pressure-wire group.


SCOUT-HCM: Mavacamten Outperforms Placebo in Adolescents With HCM, With Joseph Rossano, MD, MS


Mavacamten successfully demonstrated greater reductions in left ventricular outflow compared to placebo in adolescent patients with oHCM in the SCOUT-HCM trial. Joseph Rossano, MD, MS, co-director of the Cardiac Center at the Children’s Hospital of Philadelphia, presented the data at ACC.26, demonstrating the drug’s efficacy among 44 patients. Mean Valsalva left ventricular outflow tract gradient ultimately decreased by 48.5 mmHg in the mavacamten arm compared to -0.5 mmHg in the placebo arm, and Rossano and colleagues ultimately reported few significant adverse events.


Ultrasound-Facilitated Catheter-Directed Fibrinolysis Reduces Early Decompensation in Pulmonary Embolism


The HI-PEITHO study, investigating ultrasound-facilitated, catheter-directed fibrinolysis with anticoagulation in patients with acute, intermediate-risk pulmonary embolism (PE), has demonstrated the system’s superiority to anticoagulation alone. Among 544 patients, this catheter intervention substantially reduced the risk of early clinical deterioration – a combination outcome of incidence of PE-related death, cardiorespiratory decompensation or collapse, and symptomatic PE recurrence within 7 days occurred in 11 patients in the intervention arm compared to 28 in the control group.


CHAMPION-AF: Left Atrial Appendage Closure Noninferior to NOACs


The CHAMPION-AF trial demonstrated the noninferiority of device-based left atrial appendage closure (LAAC) compared to non-vitamin K antagonist oral anticoagulant (NOAC) therapy in preventing adverse events in patients with 

. The trial enrolled 3000 patients with non-valvular AF at elevated stroke risk, who were then randomized to either the Watchman FIx device or an approved NOAC. Ultimately, a composite primary efficacy endpoint cardiovascular death, stroke, or systemic embolism occurred in 81 patients among the device group and 65 in the NOAC group, resulting in a difference of 0.9 percentage points.


Don't Miss a Beat: MRA Updates at ACC 2026 Scientific Sessions


SPIRIT-HF ultimately showed that spironolactone did not significantly reduce a composite endpoint of 

 hospitalization and cardiovascular death compared to placebo in patients with heart failure with preserved ejection fraction (HFpEF) or mildly reduced ejection fraction (HFmrEF). In actuality, patients administered spironolactone saw an increase in hospitalizations and severe adverse events, potentially raising questions about the safety of the drug in HFpEF and HFmrEF. However, investigators noted high discontinuation due to the COVID-19 pandemic, potentially influencing the study’s capacity to conclusively demonstrate differences between the groups.


IVUS-CHIP: IVUS-Guided PCI Fails to Demonstrate Superiority in Complex Coronary Arteries

Among 2020 patients with complex coronary arteries, randomly assigned in a 1:1 ratio to either IVUS-guided PCI or angiography-guided PCI, target-vessel failure occurred in 14% of patients in the IVUS arm compared to 11% in the angiography arm. The trial failed to demonstrate IVUS-guided PCI’s superiority to angiography, with complications occurring in 11.3% of the IVUS group and 10.2% of the angiography group. Investigators ultimately declared that the industry is not currently capable of leveraging intravascular imaging data to guide PCI in a manner that justifies the increased complexity and cost of the procedure.

ACC.26 featured several high-impact trials spanning CAD physiology assessment, pediatric oHCM therapy, PE intervention, AF stroke prevention, HFpEF/HFmrEF MRAs, and complex PCI imaging. Angiography-derived FFR achieved noninferior procedural success versus pressure-wire FFR with faster assessment. In adolescents with oHCM, mavacamten produced marked LVOT gradient reductions with few significant adverse events. Ultrasound-facilitated catheter-directed fibrinolysis reduced early clinical deterioration in intermediate-risk PE. LAAC with Watchman FLX was noninferior to NOACs for major thromboembolic outcomes.

Catch up on data from some of the most impactful trials presented at the American College of Cardiology 2026.

Cardiology

Cardiology condition center page is a comprehensive resource for clinical news and insights on cardiovascular and cardiometabolic diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for heart disease and cardiovascular events, as well as associated diabetes, renal failure, and more...

Heart Failure

The HCPLive heart failure page is a resource for medical news and expert insights on HF. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for heart disease, reduced and preserved ejection fraction, and more.

Cardiomyopathy

Arrhythmia

Conference

 conference coverage page features articles, videos, and expert-led live coverage from major medical meetings throughout the year.

Strategic Alliance Partnership

ACC.26 Recap: 6 Practice-Changing Trials to Know

The first quarter of 2026 brought a series of notable US Food and Drug Administration (FDA) approvals, highlighting continued momentum in innovation across diverse therapeutic areas, including rare diseases, endocrinology, dermatology, psychiatry, and hepatology. A recurring theme was the expansion of treatment options for underserved populations, particularly pediatric and rare disease communities, alongside a growing emphasis on more convenient, patient-centered care.

Several decisions marked important firsts, including the first approved therapies for conditions like pediatric acquired thrombotic thrombocytopenic purpura (aTTP), cerebral folate deficiency, and acquired hypothalamic obesity. The FDA also advanced novel therapeutic approaches, with approvals introducing new mechanisms and classes, as well as first-in-indication treatments poised to reshape care in areas like psoriasis and cholestatic pruritus in primary biliary cholangitis (PBC).

At the same time, the quarter reflected ongoing progress in optimizing existing therapies, with higher-dose options, new pediatric indications, and innovations in drug delivery aimed at improving adherence and quality of life.

Check out this Q1 2026 FDA news month in review for a recap of HCPLive’s coverage of the top FDA approvals and research from the past few months:

FDA Approves Caplacizumab-yhdp (Cablivi) as First Pediatric aTTP Therapy

: Pediatric patients ≥ 12 years of age with aTTP in combination with plasma exchange and immunosuppressive therapy

: Approval supported by efficacy data from a retrospective chart review study of 30 patients 2-18 years of age showing 80% of patients achieved clinical remission. Builds upon caplacizumab’s initial 2019 approval for adults with aTTP and makes caplacizumab the first treatment for pediatric aTTP.

FDA Approves ProlivRx, First At-Home Neuromodulation Device for MDD

: Adults with major depressive disorder (MDD) who did not respond to ≥ 1 antidepressant

: Supported by clinical evidence from the MOOD Study, a randomized, controlled, multicenter clinical trial, evaluating Proliv Rx in MDD with inadequate response to antidepressant medications.

FDA Approves First Dual-Agent Eye Drop for Near Vision Loss

: Supported by results from a pair of pivotal phase 3 trials, BRIO I and BRIO II, conducted in adults with presbyopia. Represents the first regulatory authorization of a fixed-dose, dual-agent topical therapy for age-related near vision degradation.

FDA Approves ET-600 Desmopressin Acetate (Desmoda) for Central Diabetes Insipidus

: Central diabetes insipidus in pediatric patients

: Marks the first and only FDA-approved oral liquid formulation of desmopressin

FDA Approves 3 New Pediatric Indications for Once-Weekly Somapacitan-beco (Sogroya)

: Children ≥ 2.5 years of age with Idiopathic Short Stature (ISS), short stature born Small for Gestational Age (SGA) and with no catch-up growth by 2 years of age, or growth failure associated with Noonan Syndrome (NS)

: Supported by data from the REAL8 study as part of the ongoing REAL clinical trial program.

FDA Grants Accelerated Approval to Navepegritide for Achondroplasia in Children Aged 2 Years and Older

: Children ≥ 2 years of age with achondroplasia and open epiphyses

: Based on improvements in annualized growth velocity (AGV) from 3 phase 3 trials, with continued approval contingent on confirmatory evidence of clinical benefit

FDA Approves Leucovorin Calcium (Wellcovorin) Tablets as First Cerebral Folate Deficiency Treatment

: Adult and pediatric patients who have a confirmed variant in the folate receptor 1 gene (CFD-FOLR1)

: Based on a systematic review of the published literature on the topic, including published case reports with patient-level information, as well as mechanistic data

FDA Approves Secukinumab for Pediatric Patients 12 Years and Older with HS

: Moderate to severe hidradenitis suppurativa (HS) in pediatric patients ≥ 12 years of age

: Approval makes it the only IL-17A inhibitor for this population, adding a differentiated biologic option to an area where treatment choices for younger patients have historically been limited

Icotrokinra, an Oral Il-23 Inhibitor, Receives FDA Approval for Psoriasis

: Moderate to severe plaque psoriasis in adults and pediatric patients ≥ 12 years of age weighing ≥ 40 kg who are candidates for systemic therapy or phototherapy

: Marks the first for an oral targeted peptide selectively blocking the IL-23 receptor and introduces a new mechanistic class to the psoriasis treatment landscape backed by data from multiple trials in the phase 3 ICONIC program

FDA Approves Higher Dose Semaglutide (Wegovy HD) Injection 7.2 mg for Obesity

: To be used along with a reduced calorie diet and increased physical activity to help adults with obesity lose weight and keep it off, provided they have tolerated the 2.4 mg dosage for ≥ 4 weeks and additional weight reduction is clinically indicated

: Based on results from the STEP UP trial program, a phase 3b 72-week randomized, double-blinded, placebo-controlled and active-controlled superiority trial designed to evaluate the efficacy and safety of semaglutide injection 7.2 mg compared to semaglutide injection 2.4 mg and placebo as an adjunct to lifestyle intervention.

FDA Approves Linerixibat (Lynavoy) As First Treatment for Cholestatic Pruritus in PBC

: Cholestatic pruritus in adult patients with PBC

: Approval makes it the first medicine approved in the US for this indication, supported by data from the global phase 3 GLISTEN trial, which met both primary and key secondary endpoints, demonstrating significant, rapid and sustained improvements in cholestatic pruritus and itch-related sleep interference versus placebo

FDA Approves Setmelanotide (Imcivree) for Acquired Hypothalamic Obesity

: Acquired hypothalamic obesity in adults and pediatric patients ≥ 4 years of age

: Approval makes it the first and only FDA-approved therapy for this condition, based on data from the global, randomized, double-blind, placebo-controlled phase 3 TRANSCEND trial

FDA Approves Insulin Icodec (Awiqli) as First Once-Weekly Basal Insulin for Type 2 Diabetes

: Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes

: Makes it the first and only once-weekly basal insulin available in the US, based on results from the ONWARDS type 2 diabetes phase 3a program, which comprised 5 randomized, active-controlled, treat-to-target clinical trials in approximately 4000 adults with type 2 diabetes.

Q1 2026 FDA actions underscored sustained innovation across rare disease, endocrinology, dermatology, psychiatry, hepatology, and ophthalmology, with multiple first-in-indication approvals. Several decisions expanded pediatric access, including first therapies for pediatric aTTP and cerebral folate deficiency, and new pediatric indications in growth disorders and hidradenitis suppurativa. Patient-centric care advances included at-home neuromodulation for antidepressant-resistant MDD, an oral liquid desmopressin formulation, and once-weekly agents for diabetes and growth hormone deficiency.

A look at 13 key FDA approvals from Q1 2026, highlighting advances in rare disease, pediatrics, novel therapies, and patient-centered innovation.

FDA News

Hepatology

Obesity Management

Obesity Management condition center page, resources on the topics of medical news and expert insight into clinical weight management can be found. Content includes articles, interviews, videos, podcasts, and breaking news on obesity research, treatment, and drug development.

Endocrinology

The HCPLive endocrinology page is a comprehensive resource for clinical news and insights on endocrine system conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for diabetes, hormonal disease, and more.

Dermatology

The HCPLive dermatology page is a resource for medical news and expert insights on skin disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for dermatologic conditions, and more.

Q1 2026 Recap: Top FDA Approvals

4 Hematology Headlines You Missed in March 2026


Recent updates in hematology underscore simultaneous progress in therapeutic innovation, precision diagnostics, and efforts to standardize care across rare and complex blood disorders.

In polycythemia vera (PV), the US Food and Drug Administration (FDA) has granted Priority Review to rusfertide, a first-in-class hepcidin mimetic targeting iron dysregulation, based on phase 3 VERIFY and supportive long-term data demonstrating improved hematocrit control, reduced phlebotomy requirements, and symptom relief versus standard of care.

In parallel, the American Society of Hematology (ASH) has released updated guidelines for severe and very severe acquired aplastic anemia, outlining 33 recommendations and 4 good practice statements. The guidance emphasizes earlier use of genetic and diagnostic testing, individualized treatment strategies, including immunosuppressive therapy with eltrombopag, and clearer pathways to second-line care to improve outcomes in this high-risk population.

Advances in molecular diagnostics are also reshaping hematologic malignancy care, with rapid next-generation sequencing (NGS) enabling faster identification of actionable mutations to guide early treatment decisions. However, uneven access, variability in reporting, and infrastructure limitations continue to constrain real-world implementation, highlighting a persistent gap between technological capability and clinical deployment.

At the same time, workforce data highlight ongoing system-level strain, with hematology-oncology physicians treating sickle cell disease reporting higher burnout rates than peers despite similar levels of resilience. Together, these developments reflect a field advancing rapidly in scientific capability while still facing significant challenges in equitable access, implementation, and provider sustainability.

Catch up on the 4 headlines you missed from March 2026:

FDA Accepts New Drug Application for Rusfertide, Grants Priority Review In Polycythemia Vera

The FDA has accepted the New Drug Application for rusfertide and granted Priority Review, positioning the investigational therapy as a potential first-in-class option for polycythemia vera (PV). Based on phase 3 VERIFY and supportive long-term data, rusfertide demonstrated improved hematocrit control, reduced phlebotomy needs, and symptom benefits compared with standard care alone.

The hepcidin mimetic, which targets iron dysregulation underlying PV, was generally well tolerated, with mostly low-grade adverse events reported. A PDUFA decision is expected in the third quarter of 2026.

Burnout in Sickle Cell Physicians Hits 60% While Grit and Resilience Stand Strong

Burnout rates were higher among hematology-oncology physicians treating sickle cell disease (60%) versus those who do not (43%), despite similar levels of grit and resilience. Survey findings suggest systemic factors, rather than individual behaviors, are driving the disparity, with lower job pride, reduced recreation time, and compensation differences contributing to increased burnout.

Timing Is Everything: Advancing Genomic Testing in Hematologic Malignancies

Rapid next-generation sequencing (NGS) is improving precision care in hematologic malignancies by enabling timely identification of actionable mutations to guide early treatment decisions. However, adoption remains uneven, with barriers including limited expertise, inconsistent reporting, and variability in access and reimbursement across health systems.

ASH Publishes Guidelines on Diagnosis and Management of Severe and Very Severe Acquired Aplastic Anemia

ASH has released updated guidelines outlining 33 recommendations and 4 good practice statements for the diagnosis and management of severe and very severe acquired aplastic anemia.

The guidance emphasizes improved diagnostic strategies, including expanded genetic testing, and supports personalized treatment approaches such as early use of eltrombopag alongside immunosuppressive therapy and timely transition to second-line options. Aimed at improving outcomes in this rare but life-threatening condition, the recommendations also seek to expand access to appropriate therapies and standardize care across patient populations.

Regulatory and guideline activity highlights momentum across benign and malignant hematology while exposing implementation and workforce fragility. Rusfertide, a hepcidin mimetic addressing iron dysregulation in polycythemia vera, has received FDA Priority Review on phase 3 and long-term data showing superior hematocrit control, fewer phlebotomies, and symptom improvement with mostly low-grade toxicities; a PDUFA decision is expected in Q3 2026. Updated ASH guidance for severe acquired aplastic anemia prioritizes earlier genetic workup and individualized therapy, including eltrombopag with immunosuppression. Rapid NGS is accelerating actionable mutation detection, but access and reporting heterogeneity persist. Sickle cell clinicians report disproportionately high burnout.

Catch up on the hematology headlines you missed in March 2026. 

Hematology

4 Hematology Headlines You Missed In March 2026

On April 6, 2026, Amgen announced positive topline results from a phase 3 trial of teprotumumab-trbw (Tepezza), administered via an on-body injector (OBI), for the treatment of moderate-to-severe 

Tepezza was first approved by the US Food and Drug Administration in 2020 and is the first and only approved medicine for TED. It is designed to reduce proptosis and double vision – 2 hallmark symptoms of TED – and has demonstrated its efficacy across several global clinical studies. Additionally, the drug’s safety and efficacy are well-established via 6 years of real-world experience in >25,000 patients.

“These results extend and support the best-in-class efficacy of Tepezza for people living with thyroid eye disease, now with subcutaneous administration delivering IV-level efficacy,” Jay Bradner, MD, executive vice president of research and development at Amgen, said in a statement. “With a well-understood mechanism and established impact in the clinic, we can evolve how the medicine is delivered to potentially reach even more patients through a more convenient subcutaneous option.”

The present study was a randomized, double-masked, placebo-controlled, parallel-group, multicenter trial, aiming to evaluate the efficacy and safety of subcutaneously administered Tepezza in patients with active TED compared to placebo. Investigators included a primary endpoint of proptosis responder rate, measured as the percentage of participants with a ≥2mm reduction from baseline in the study eye without deterioration of proptosis in the fellow eye by week 24.

To be eligible for inclusion, patients had to have a diagnosis of moderate-to-severe active TED within 15 months and proptosis of ≥3 mm from baseline prior to TED diagnosis, among other criteria. Patients were administered Tepezza or placebo via an OBI every 2 weeks, totaling to 12 injections.

Ultimately, the trial met its primary endpoint, reflecting a statistically significant and clinically meaningful 77% proptosis response rate (76.7% Tepezza OBI vs 19.6% placebo; 

 <.0001). Additionally, the mean proptosis reduction was -3.17 mm by week 24 (-3.17mm Tepezza OBI vs -0.8 mm placebo; 

Investigators also saw significant improvements in overall responder rate, the percentage of patients achieving a Clinical Activity Score (CAS) of 0 or 1, change in diplopia as ordinal response categories, diplopia response rate, and mean change from baseline in week 24 in the Graves’ Ophthalmology Quality of Life (GO-QoL) appearance subscale, among other secondary endpoints. Despite not achieving statistical significance, the team saw a numerical trend in the mean change in baseline at week 24 in the GO-QoL visual functioning subscale favoring Tepezza OBI.

“Thyroid eye disease can be a profoundly debilitating condition, affecting not only vision but also daily functioning with symptoms like double vision and eye bulging,” Madhura Tamhankar, MD, professor of ophthalmology and neurology at the Scheie Eye Institute, University of Pennsylvania, said in a statement. “Expanding administration options through subcutaneous delivery opens the possibility of a more accessible experience for patients with thyroid eye disease and is critical to serving diverse patient needs. The potential to achieve comparable efficacy to IV makes this advancement compelling.”

Amgen. Amgen Announces Positive Topline Phase 3 Results for Subcutaneous Tepezza in Adults Living With Moderate-to-Severe Active Thyroid Eye Disease. April 6, 2026. Accessed April 6, 2026. 

https://investors.amgen.com/news-releases/news-release-details/amgen-announces-positive-topline-phase-3-results-subcutaneous

US Food and Drug Administration. FDA approves first treatment for thyroid eye disease. 

. January 21, 2020. Accessed April 6, 2026. 

https://www.prnewswire.com/news-releases/fda-approves-first-treatment-for-thyroid-eye-disease-300990621.html

Amgen reported positive phase 3 topline data for teprotumumab-trbw delivered subcutaneously via an on-body injector in moderate-to-severe active thyroid eye disease. In a randomized, double-masked, placebo-controlled trial, dosing every two weeks for 12 injections achieved a 77% proptosis responder rate at week 24, with a mean proptosis reduction of 3.17 mm, both highly significant versus placebo. Secondary endpoints improved, including CAS, diplopia metrics, overall response, and GO-QoL appearance, supporting IV-like efficacy with greater delivery convenience.

Amgen has announced positive topline results from their phase 3 trial comparing teprotumumab-trbw – administered via an on-body injector – to placebo.

News Report

Ophthalmology

Ophthalmology page, resources on the topics of medical news and expert insight into ophthalmic disease can be found. Content includes articles, interviews, videos, podcasts, and breaking news on eye disease research, treatment, and drug development.

Thyroid Disorders

Tepezza OBI Achieves Proptosis Reduction in Thyroid Eye Disease in Phase 3 Trial

Alex Hillenbrand is an assistant editor for 

. She earned her BA in English from Lafayette College in 2023 and went on to write for pop culture, entertainment, and sports media outlets before joining MJH Life Sciences in 2025. In her free time, Alex enjoys cooking, going on walks, and meeting new people. Contact her at mjhlifesciences.com.

Catch up on the guideline updates, trial news, and featured content from March 2026. 


Nephrology

The HCPLive nephrology page is a resource for medical news and expert insights on kidney disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in nephrology, and more.

Chronic Kidney Disease

IgA Nephropathy

The HCPLive Berger disease page is a resource for medical news and expert insights on IgA nephropathy. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in Berger disease, and more.

5 Nephrology Headlines You Missed in March 2026

Diana Isaacs, PharmD, is an endocrine clinical pharmacist, director of Education and Training in Diabetes Technology, and codirector of Endocrine Disorders in Pregnancy at the Cleveland Clinic.

Podcasts

This episode discusses the recently released algorithm for T2D from the American Association of Clinical Endocrinology.

Type 2 Diabetes

Diabetes Dialogue

Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives is a monthly podcast hosted by Diana Isaacs, PharmD, and Natalie Bellini, DNP, aimed at providing a regular roundup of the latest clinically applicable insights across diabetes and metabolic diseases, with a focus on leveraging technology to improve care.

Videos

podcasts page features a feed of medical news and interview podcast series, including DocTalk, Lungcast, Derm Discussions, and Heart Trials.

Diabetes Dialogue: 2026 AACE Guidelines for Type 2 Diabetes

Victoria Johnson joined MJH Life Sciences in 2020 and has written for NeurologyLive, CGTLive, and is now an assistant managing editor for HCPLive and RheumatologyLive. She doesn’t have enough time for her numerous hobbies. You can reach her at vjohnson@mjhlifesciences.com.

Check out 6 FDA decisions to watch in Q2 2026, listed chronologically by expected decision date.

Pulmonology

Infectious Disease condition center page is a comprehensive resource for clinical news and insights on respiratory health. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for asthma, COPD, interstitial lung disease, COVID-19, and more.

Q2 2026 Preview: 6 FDA Decisions to Watch

Luke Laffin, MD, is the co-director of the Center for Blood Pressure Disorders, medical director of cardiac rehabilitation, and associate professor of medicine at Cleveland Clinic.

Laffin discusses results from the Kardinal study, which investigated a single dose of tonlamarsen followed by placebo against monthly tonlamarsen treatment in hypertension.

Hypertension

The HCPLive hypertension page is a resource for medical news and expert insights on high blood pressure. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for hypertension, and more.

Tonlamarsen Lowers Angiotensinogen, Mixed Results for Blood Pressure, With Luke Laffin, MD

Eingun James Song, MD, is the director of clinical research for Frontier Dermatology. 

In this AAD interview, Song highlights how he views the potential benefit of amlitelimab in light of discontinuing rocatinlimab.

Atopic Dermatitis

Atopic Dermatitis condition center page, audiences can find a variety of coverage mediums for medical news and updates, including articles, video interviews, podcasts, and breaking news on dermatitis research, treatment, and drug development.

Discussing Future of Amlitelimab, OX40/OX40L Treatment, With Eingun James Song, MD

Read 6 updates from the meeting that clinicians managing atopic dermatitis should know.

AAD 2026: 6 Atopic Dermatitis Trials to Know

Future directions in ISM, including evolving treatment goals, unanswered questions about osteoporosis, anaphylaxis, resistance, curative strategies, and the need to extend advances to pediatric populations.

Latest News

6 Psychiatry Headlines You Missed in March 2026

ACC.26 Recap: 6 Practice-Changing Trials to Know

Q1 2026 Recap: Top FDA Approvals

4 Hematology Headlines You Missed In March 2026

Tepezza OBI Achieves Proptosis Reduction in Thyroid Eye Disease in Phase 3 Trial